Pharmacokinetics Pharmacodynamics and Safety of LY01022 in Patients With Prostate Cancer Compared With Zoladex® 10.8mg

NCT05856630 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Goserelin Acetate Sustained-Release Microspheres for Injection
DRUG: Zoladex 10.8 MG Drug Implant

Sponsor

Luye Pharma Group Ltd.